[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”50px|||||” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”16px” custom_margin=”||60px||false|false” global_colors_info=”{}”]<\/p>\n
Prof.ssa Canonico, Dott. Tiboni, Dott.ssa Montanari, Prof Casettari, Prof Guescini, Prof.ssa Rossi, Prof Magnani<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” locked=”on” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Extracellular vesicles (EVs) are promising natural nanocarriers for the delivery of therapeutic\u00a0 <\/span>agents. As with any other kind of cell, red blood cells (RBCs) produce a limited number of EVs under\u00a0 <\/span>physiological and pathological conditions. Thus, RBC-derived extracellular vesicles (RBCEVs) have\u00a0 <\/span>been recently suggested as next-generation delivery systems for therapeutic purposes. In this\u00a0 <\/span>paper, we show that thanks to their unique biological and physicochemical features, RBCs can\u00a0 <\/span>be efciently pre-loaded with several kinds of molecules and further used to generate RBCEVs. A\u00a0 <\/span>physical vesiculation method, based on \u201csoft extrusion\u201d, was developed, producing an extremely\u00a0 <\/span>high yield of cargo-loaded RBCEV mimetics. The RBCEVs population has been deeply characterized\u00a0 <\/span>according to the new guidelines MISEV2023, showing great homogeneity in terms of size, biological\u00a0 <\/span>features, membrane architecture and cargo. In vitro preliminary results demonstrated that RBCEVs\u00a0 <\/span>are abundantly internalized by cells and exert peculiar biological efects. Indeed, efcient loading and\u00a0 <\/span>delivery of miR-210 by RBCEVs to HUVEC has been proven, as well as the inhibition of a known mRNA\u00a0 <\/span>target. Of note, the bench-scale process can be scaled-up and translated into clinics. In conclusion, this\u00a0 <\/span>investigation could open the way to a new biomimetic platform for RNA-based therapies and\/or other\u00a0 <\/span>therapeutic cargoes useful in several diseases.<\/span><\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px|||” locked=”on” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” min_height=”20.8px” global_colors_info=”{}”]<\/p>\nKeyword<\/h4>\n